Although [177Lu]Lu-DOTA-folate or anti-CTLA-4 therapy alone had a minimal impact on tumor growth and survival, which did not significantly enhance survival time in mice compared to control groups, their combination resulted in marked tumor growth inhibition and prolonged survival beyond 70 days without noticeable side effects. Here, CTLA4 is linked to neoplasm.